[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595018":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":81,"collaborators":84,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":91,"sex":97,"minAge":98,"maxAge":26,"enrollmentInfo":99,"targetDuration":26,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":71,"whyStopped":26,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Huashan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Colchicine group","EXPERIMENTAL","Patients in this arm will receiver oral colchicine 0.5mg once per day for 1 year combined with standard treatment",[13],"Drug: Colchicine 0.5mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Patients in this arm will receiver oral matching placebo once per day for 1 year combined with standard treatment",[19],"Drug: Matching placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Colchicine 0.5mg","Oral colchicine 0.5mg once per day combined with standard treatment",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Matching placebo","Oral matching placebo once per day combined with standard treatment",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Xin Cheng, MD, PhD","CONTACT","+86 021-52887145","chengxin@fudan.edu.cn",[38,56,69],{"facility":39,"status":40,"city":41,"state":26,"zip":26,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","NOT_YET_RECRUITING","Beijing","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.39723,39.9075,{"lat":48,"lon":47},[51,54],{"name":52,"role":34,"phone":26,"phoneExt":26,"email":53},"Jun Ni, MD, PhD","pumchnijun@163.com",{"name":52,"role":55,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"facility":57,"status":40,"city":58,"state":26,"zip":26,"country":42,"countryCode":43,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"West China Hospital, Sichuan University","Chengdu",{"type":45,"coordinates":60},[61,62],104.06667,30.66667,{"lat":62,"lon":61},[65,68],{"name":66,"role":34,"phone":26,"phoneExt":26,"email":67},"Bo Wu, MD, PhD","drwubo@wchscu.cn",{"name":66,"role":55,"phone":26,"phoneExt":26,"email":26},{"facility":70,"status":71,"city":72,"state":26,"zip":26,"country":42,"countryCode":43,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Huashan Hospital, Fudan University","RECRUITING","Shanghai",{"type":45,"coordinates":74},[75,76],121.45806,31.22222,{"lat":76,"lon":75},[79,80],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"name":33,"role":55,"phone":26,"phoneExt":26,"email":26},{"type":55,"investigatorFullName":82,"investigatorTitle":83,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Xin Cheng","Professor and Vice Chair, Department of Neurology, Huashan Hospital, Fudan University",[85,87],{"name":86,"class":6},"Peking Union Medical College Hospital",{"name":88,"class":6},"West China Hospital","100595018","phase-2-colchicine-for-the-prevention-of-recurrence-in-cerebral-amyloid-angiopathy-related-intracerebral-hemorrhage-100595018",false,"NCT07026994","Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage","Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage (CARE-ICH)","CARE-ICH","Inclusion Criteria:\n\n* Age ≥55 years;\n* Diagnosed with \"probable CAA with supporting pathology\" or \"probable CAA\" according to the modified Boston criteria (version 1.5);\n* High risk of recurrent ICH, defined as: 1 prior symptomatic ICH and presence of cortical superficial siderosis (cSS), or ≥2 prior symptomatic ICHs;\n* Time interval since symptom onset of the most recent ICH: ≤3 months (earlier enrollment is preferred if criteria are met);\n* Modified Rankin Scale (mRS) score ≤4 at randomization;\n* Written informed consent from the participant or their legally authorized representative before study enrollment.\n\nExclusion Criteria:\n\n* Secondary causes of ICH;\n* Pre-existing moderate-to-severe renal, liver or blood disorders (anaemia \\[hemoglobin \\\u003C10g\u002FdL\\], thrombocytopaenia \\[platelet count \\\u003C100×109\u002FL\\], leucopenia \\[white blood cell \\\u003C3×109\u002FL\\], cirrhosis or severe hepatic dysfunction, renal insufficiency \\[estimated glomerular filtration rate (eGFR) \\\u003C15mL\u002Fmin\\]);\n* Prior diagnosis of gout, peripheral neuropathy, myopathy, inflammatory bowel disease or chronic diarrhea;\n* Concurrent treatment with regular immune-suppressant (corticosteroids, cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab), moderate-to-strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir\u002Fritonavir, indinavir, itraconazole, ketoconazole, lopinavir\u002Fritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir\u002Fritonavir) or P-glycoprotein inhibitors (cyclosporine, ranolazine);\n* Known allergy, sensitivity or intolerance to colchicine;\n* Contraindications or inability to complete brain MRI or susceptibility weighted imaging (SWI) scans;\n* Pregnancy or breastfeeding;\n* Recent participation in any other interventional study in the past 30 days before enrollment;\n* Not expected to survive the follow-up period;\n* Inability to adhere to study procedures;\n* Any condition in which investigators believe that participating in this study may be harmful to the patient.","ALL","55 Years",{"count":100,"type":101},80,"ESTIMATED","INTERVENTIONAL",[104],"PHASE2","The goal of this clinical trial is to assess the safety and tolerability of colchicine for preventing intracerebral haemorrhage (ICH) recurrence in patients with cerebral amyloid angiopathy (CAA)-ICH at high risk of recurrence.\n\nThe main questions it aims to answer are:\n\n* Is colchicine safe for CAA-ICH patients?\n* Is colchicine well tolerated for CAA-ICH patients? Researchers will compare colchicine to a placebo (a look-alike substance that contains no drug) to see if colchicine is safe and tolerable for CAA-ICH patients and works to prevent ICH recurrence.\n\nParticipants will:\n\n* Take colchicine or a placebo every day for 12 months\n* Receive telephone follow-ups at 3 and 9 months, and visit the clinic at 6 and 12 months for checkups and tests\n* Control blood pressure and improve lifestyle",[107,108],"Cerebral Amyloid Angiopathy","Intracerebral Hemorrhage Lobar",[107,110,111,112],"Intracerebral Hemorrhage","Colchicine","Recurrence","2025-06-22",{"date":115,"type":116},"2025-06-26","ACTUAL",{"date":118,"type":116},"2025-06-18",{"date":120,"type":101},"2027-12",{"name":5,"class":6},3]